Anti-estrogen-based endocrine therapies, such as the ERα modulator Tamoxifen, ERα degrader Fulvestrant, and the aromatase inhibitor Letrozole, have significantly enhanced the survival rates of patients with hormone receptor-positive (HR+) breast cancer [5]. Here, ESR1 is linked to breast carcinoma.